MSCs demonstrate promise against COVID-19—related respiratory distress

A preclinical trial from Cynata Therapeutics (Melbourne, Australia) has produced positive results for a mesenchymal stem cell product against COVID-19—related respiratory distress. Clinical-stage biotechnology company Cynata Therapeutics (Melbourne, Australia) has published positive results from a preclinical trial utilizing Cymerusâ„¢ mesenchymal stem cells (MSCs) in the treatment of acute respiratory distress syndrome (ARDS). ARDS can develop as a complication of infections such as COVID-19 and pneumonia, and is the leading cause of death associated with the conditions. The study, published in the American Journal of Respiratory and Critical Care Medicine, was conducted in sheep and demonstrated that a 24-hour endobronchial infusion...